- Report
- March 2024
- 188 Pages
Global
From €3217EUR$3,374USD£2,742GBP
€3574EUR$3,749USD£3,046GBP
- Report
- January 2024
- 200 Pages
Global
From €4767EUR$5,000USD£4,063GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2860EUR$3,000USD£2,438GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1907EUR$2,000USD£1,625GBP
The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more